RxDoctor Payments Data

Hina Azmat, MD

Internal Medicine · Deltona, FLNPI 1154567642

Payments from drug & device makers

$355in general payments, 2019–2025

Across 18 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$183
  • Insmed, Inc.$55
  • AbbVie$50
  • Abbott$20
  • AstraZeneca$17
  • Novartis$15
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$32090%
  • Education$3510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk8$183
Insmed, Inc.3$55
AbbVie3$50
Abbott1$20
AstraZeneca1$17
Novartis1$15
Kyowa Kirin, Inc.1$15

How this compares

$355 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$93,959
Medicare patients
177
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$99,068
OzempicSemaglutide58$90,853
TrulicityDulaglutide27$48,337
JanuviaSitagliptin Phosphate15$21,906
XareltoRivaroxaban17$19,994
FarxigaDapagliflozin Propanediol13$13,755
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$9,068
SymbicortBudesonide/Formoterol Fumarate20$8,404
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$6,127
Albuterol Sulfate HfaAlbuterol Sulfate94$4,579
Rosuvastatin Calcium217$3,682
Gabapentin164$3,457
Ventolin HfaAlbuterol Sulfate31$3,427
Levothyroxine Sodium379$3,277
Losartan Potassium273$2,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$183$90,85358 claims
AstraZenecaFarxiga, Symbicort$17$22,15933 claims
AbbVieSynthroid$50$1,70931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Deltona

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →